Jennifer Lew Sells 6,360 Shares of Aduro Biotech Inc. (ADRO) Stock
Aduro Biotech Inc. (NASDAQ:ADRO) insider Jennifer Lew sold 6,360 shares of the stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $14.95, for a total value of $95,082.00. Following the transaction, the insider now owns 48,955 shares in the company, valued at $731,877.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Aduro Biotech Inc. (NASDAQ:ADRO) opened at 14.68 on Thursday. The stock has a 50 day moving average price of $14.76 and a 200-day moving average price of $13.15. Aduro Biotech Inc. has a 12-month low of $7.26 and a 12-month high of $34.95. The stock’s market capitalization is $950.59 million.
Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.21. Aduro Biotech had a negative return on equity of 9.23% and a negative net margin of 23.69%. The company had revenue of $39 million for the quarter, compared to the consensus estimate of $25.24 million. The business’s quarterly revenue was up 306.3% compared to the same quarter last year. Equities research analysts expect that Aduro Biotech Inc. will post ($1.39) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/jennifer-lew-sells-6360-shares-of-aduro-biotech-inc-adro-stock.html
ADRO has been the topic of several recent analyst reports. Zacks Investment Research downgraded Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Monday, July 18th. Canaccord Genuity reiterated a “buy” rating and set a $30.00 target price on shares of Aduro Biotech in a research report on Friday, August 5th. FBR & Co reiterated a “buy” rating on shares of Aduro Biotech in a research report on Monday, June 6th. Finally, Roth Capital reiterated a “buy” rating and set a $22.00 target price on shares of Aduro Biotech in a research report on Monday, July 11th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Aduro Biotech presently has an average rating of “Hold” and an average price target of $22.00.
Several hedge funds have recently bought and sold shares of the company. Sphera Funds Management LTD. boosted its position in shares of Aduro Biotech by 41.7% in the first quarter. Sphera Funds Management LTD. now owns 170,000 shares of the company’s stock worth $2,178,000 after buying an additional 50,000 shares during the last quarter. American Century Companies Inc. bought a new position in shares of Aduro Biotech during the second quarter worth about $1,265,000. State Street Corp boosted its position in shares of Aduro Biotech by 33.0% in the first quarter. State Street Corp now owns 160,860 shares of the company’s stock worth $2,062,000 after buying an additional 39,952 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Aduro Biotech by 0.6% in the first quarter. Franklin Resources Inc. now owns 893,210 shares of the company’s stock worth $11,442,000 after buying an additional 5,527 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Aduro Biotech by 68,112.7% in the first quarter. Acadian Asset Management LLC now owns 53,888 shares of the company’s stock worth $691,000 after buying an additional 53,809 shares during the last quarter. 29.76% of the stock is currently owned by institutional investors.
Aduro Biotech Company Profile
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.